Alkermes plc (ALKS) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Alkermes plc (ALKS) Launches Investigational Product Designed for Initiation Onto ARISTADA for Treatment of Schizophrenia
October 26, 2017 7:44 AM EDTAlkermes plc (NASDAQ: ALKS) today unveiled Aripiprazole Lauroxil NanoCrystal® Dispersion (ALNCD), a novel, investigational product designed for initiation onto ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. ALNCD leverages the companys proprietary NanoCrystal technology and is designed to provide extended-release aripiprazole lauroxil in a formulation using a smaller... More
